Digbi Health Expands its Multi-Condition Care Platform to Enhance Efficacy and Adherence to GLP-1 Drugs
17 janv. 2025 05h21 HE
|
Digbi Health
PALO ALTO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Digbi Health, a pioneer in Precision Biology, is advancing obesity management with groundbreaking enhancements to GLP-Compass (™), its...
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
10 janv. 2025 08h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Americans Weigh In: International Food Information Council Releases New Research Examining Perceptions Around Obesity & Weight Loss Medications
08 janv. 2025 11h23 HE
|
International Food Information Council Foundation
Washington, DC, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The International Food Information Council (IFIC) has published a new survey examining Americans’ attitudes and perceptions toward obesity...
Semaglutides Market Research Report 2024-2028 & 2033 Featuring Major Players, Pfizer, Roche, Merck, AbbVie, and Sanofi
06 janv. 2025 04h12 HE
|
Research and Markets
Dublin, Jan. 06, 2025 (GLOBE NEWSWIRE) -- The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering.This Semaglutides market report covers market...
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
09 déc. 2024 08h00 HE
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscl
CORRECTION - Elevai Labs Inc.
14 nov. 2024 14h35 HE
|
Elevai Labs Inc.
/CORRECTION/ Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
14 nov. 2024 09h08 HE
|
Elevai Labs Inc.
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
30 oct. 2024 08h30 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
New Study Finds Trimsulin Achieves 243% Greater Weight Loss than Semaglutide without Serious Side Effects
24 oct. 2024 08h30 HE
|
FirstFitness Nutrition
New Study Finds Trimsulin Achieves 243% Greater Weight Loss than Semaglutide without Side Effects Offering a Natural GLP-1 Alternatative for Weight Loss.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
22 oct. 2024 09h54 HE
|
Elevai Labs Inc.
Elevai Biosciences Engages Leading CRO to Support Regulatory Planning Efforts and Pre-IND Meeting with the FDA for EL-22 For The Treatment of Obesity